Noboru Yamamoto

Noboru Yamamoto

UNVERIFIED PROFILE

Are you Noboru Yamamoto?   Register this Author

Register author
Noboru Yamamoto

Noboru Yamamoto

Publications by authors named "Noboru Yamamoto"

Are you Noboru Yamamoto?   Register this Author

100Publications

2286Reads

38Profile Views

Impact of low-dose anti-thymocyte globulin on immune reconstitution after allogeneic hematopoietic cell transplantation.

Int J Hematol 2020 Jan 22;111(1):120-130. Epub 2019 Oct 22.

Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-0016, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12185-019-02756-1DOI Listing
January 2020

Phase I study of TAS-115, a novel oral multi-kinase inhibitor, in patients with advanced solid tumors.

Invest New Drugs 2019 Dec 10. Epub 2019 Dec 10.

Department of Experimental Therapeutics, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10637-019-00859-4DOI Listing
December 2019

Improved survival among patients enrolled in oncology phase 1 trials in recent decades.

Cancer Chemother Pharmacol 2019 Nov 19. Epub 2019 Nov 19.

Department of Experimental Therapeutics, National Cancer Center Hospital, 5-1-1, Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-019-03992-2DOI Listing
November 2019

Global trends in the distribution of cancer types among patients in oncology phase I trials, 1991-2015.

Invest New Drugs 2019 02 7;37(1):166-174. Epub 2018 Aug 7.

Department of Experimental Therapeutics, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10637-018-0654-1DOI Listing
February 2019

Phase II Study of Crizotinib in East Asian Patients With ROS1-Positive Advanced Non-Small-Cell Lung Cancer.

J Clin Oncol 2018 05 29;36(14):1405-1411. Epub 2018 Mar 29.

Yi-Long Wu and Jin-Ji Yang, Guangdong General Hospital and Guangdong Academy of Medical Sciences, Guangzhou; Shun Lu, Jiao Tong University, Shanghai; Jianying Zhou, First Affiliated Hospital of Zhejiang University, Hangzhou, People's Republic of China; James Chih-Hsin Yang, National Taiwan University Hospital and National Taiwan University Cancer Center, Taipei, Republic of China; Dong-Wan Kim, Seoul National University Hospital; Myung-Ju Ahn, Samsung Medical Center, Seoul, South Korea; Takashi Seto, National Kyushu Cancer Center, Fukuoka; Noboru Yamamoto, National Cancer Center Hospital, Tokyo; Toshiaki Takahashi, Shizuoka Cancer Center, Shizuoka; Takeharu Yamanaka, Yokohama City University School of Medicine, Yokohama; Koichi Goto, National Cancer Center Hospital East, Kashiwa, Japan; Allison Kemner and Debasish Roychowdhury, OxOnc Development, Princeton, NJ; Nirvan Consultants, Lexington, MA; Jolanda Paolini and Tiziana Usari, Pfizer, Milan, Italy; and Keith D. Wilner, Pfizer, La Jolla, CA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.75.5587DOI Listing
May 2018

Safety and pharmacokinetics of DS-6051b in Japanese patients with non-small cell lung cancer harboring fusions: a phase I study.

Oncotarget 2018 May 4;9(34):23729-23737. Epub 2018 May 4.

Department of Thoracic Oncology, National Hospital Organization Kyushu Cancer Center, Minami-ku, Fukuoka-shi, Fukuoka 811-1395, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18632/oncotarget.25263DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5955103PMC
May 2018

Do all patients in the phase I oncology trials need to be hospitalized? Domestic but outstanding issues for globalization of drug development in Japan.

Int J Clin Oncol 2017 Aug 14;22(4):780-785. Epub 2017 Mar 14.

Department of Experimental Therapeutics, National Cancer Center Hospital, 5-1-1, Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10147-017-1108-zDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5533862PMC
August 2017

Efficacy and safety of osimertinib in a Japanese compassionate use program.

Jpn J Clin Oncol 2017 Jul;47(7):625-629

Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jjco/hyx050DOI Listing
July 2017

Surveillance of protocol deviations in Japanese oncology registration trials: a single institute experience.

Invest New Drugs 2017 06 1;35(3):392-396. Epub 2017 Feb 1.

Clinical Trial Coordination and Support Office, National Cancer Center Hospital, Tokyo, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10637-017-0434-3DOI Listing
June 2017

PD-L1 expression in neuroendocrine tumors of the lung.

Lung Cancer 2017 06 24;108:115-120. Epub 2017 Mar 24.

Department of Thoracic Oncology, National Cancer Center Hospital, Tsukiji 5-1-1, Chuo-ku, Tokyo 104-0045, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lungcan.2017.03.006DOI Listing
June 2017

Phase I study of Nivolumab, an anti-PD-1 antibody, in patients with malignant solid tumors.

Invest New Drugs 2017 04 8;35(2):207-216. Epub 2016 Dec 8.

Department of Thoracic Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji Chuo-ku, Tokyo, 104-0045, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10637-016-0411-2DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5352798PMC
April 2017

Strategies for Utilizing Neuroimaging Biomarkers in CNS Drug Discovery and Development: CINP/JSNP Working Group Report.

Int J Neuropsychopharmacol 2017 04;20(4):285-294

National Institutes for Quantum and Radiological Science and Technology, Chiba, Japan (Drs Suhara, Higuchi, Takado, Maeda, and Yamada); Taisho Pharmaceutical Co., Ltd., Saitama, Japan (Drs Chaki and Omura); Takeda Pharmaceutical Co., Ltd., Kanagawa, Japan (Drs Kimura and Furusawa); Astellas Pharma Inc., Ibaraki, Japan (Drs Matsumoto and Miyoshi); Eisai Co., Ltd., Tokyo, Japan (Drs Ogura and Yamamoto); Mochida Pharmaceutical Co., Ltd., Tokyo, Japan (Dr Negishi); Mitsubishi Tanabe Pharma Co., Kanagawa, Japan (Dr Saijo); Daiichi Sankyo Co., Ltd., Tokyo, Japan (Dr Watanabe); Chugai Pharmaceutical Co., Ltd, Kanagawa, Japan (Dr Nakatani); Ono Pharmaceutical Co., Ltd., Osaka, Japan (Dr Liou); Hiroshima University, Hiroshima, Japan (Drs Okamoto and Yamawaki); Nippon Medical School, Tokyo, Japan (Dr Okubo); Fukushima Medical University, Fukushima, Japan (Dr Ito); Astellas Research Institute of America LLC, IL, USA (Dr Walton).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/ijnp/pyw111DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5604546PMC
April 2017

Phase I study of the second-generation, recombinant, human EGFR antibody necitumumab in Japanese patients with advanced solid tumors.

Cancer Chemother Pharmacol 2016 Nov 15;78(5):995-1002. Epub 2016 Sep 15.

Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-016-3154-zDOI Listing
November 2016

Comprehensive screening of target molecules by next-generation sequencing in patients with malignant solid tumors: guiding entry into phase I clinical trials.

Mol Cancer 2016 11 16;15(1):73. Epub 2016 Nov 16.

Department of Experimental Therapeutics, Exploratory Oncology Research & Clinical Center, National Cancer Center, 5-1-1, Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12943-016-0553-zDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5112718PMC
November 2016

Effect of mental practice using inverse video of the unaffected upper limb in a subject with chronic hemiparesis after stroke.

J Phys Ther Sci 2016 Oct 28;28(10):2984-2987. Epub 2016 Oct 28.

Unit of Rehabilitation Sciences, Nagasaki University Graduate School of Biomedical Sciences, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1589/jpts.28.2984DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5088165PMC
October 2016

Utility of ferritin as a predictor of the patients with Kawasaki disease refractory to intravenous immunoglobulin therapy.

Mod Rheumatol 2015 27;25(6):898-902. Epub 2015 May 27.

b Department of Pediatrics , School of Medicine, University of Occupational and Environmental Health , Kitakyushu , Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3109/14397595.2015.1038430DOI Listing
September 2016

Simultaneous optimization of limited sampling points for pharmacokinetic analysis of amrubicin and amrubicinol in cancer patients.

Asia Pac J Clin Oncol 2016 Sep 7;12(3):259-64. Epub 2016 Mar 7.

Department of Pharmacy, National Cancer Center Hospital, Tokyo, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ajco.12485DOI Listing
September 2016

Phase 1 study of abemaciclib, an inhibitor of CDK 4 and 6, as a single agent for Japanese patients with advanced cancer.

Cancer Chemother Pharmacol 2016 Aug 16;78(2):281-8. Epub 2016 Jun 16.

Department of Experimental Therapeutics, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-016-3085-8DOI Listing
August 2016

Tremelimumab-associated tumor regression following after initial progression: two case reports.

Immunotherapy 2016 2;8(1):9-15. Epub 2015 Oct 2.

Department of Experimental Therapeutics, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.

View Article

Download full-text PDF

Source
https://www.futuremedicine.com/doi/10.2217/imt.15.89
Publisher Site
http://dx.doi.org/10.2217/imt.15.89DOI Listing
June 2016

Phase I trial of volasertib, a Polo-like kinase inhibitor, in Japanese patients with advanced solid tumors.

Invest New Drugs 2016 Feb 2;34(1):66-74. Epub 2015 Dec 2.

Department of Thoracic Oncology, National Cancer Centre Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10637-015-0300-0DOI Listing
February 2016

Candidates for Intensive Local Treatment in cIIIA-N2 Non-Small Cell Lung Cancer: Deciphering the Heterogeneity.

Int J Radiat Oncol Biol Phys 2016 Jan 26;94(1):155-162. Epub 2015 Sep 26.

Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan; Advanced Clinical Research of Cancer, Juntendo University Graduate School of Medicine, Tokyo, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ijrobp.2015.09.026DOI Listing
January 2016

A novel method for evaluating antibody-dependent cell-mediated cytotoxicity by flowcytometry using cryopreserved human peripheral blood mononuclear cells.

Sci Rep 2016 Jan 27;6:19772. Epub 2016 Jan 27.

Department of Clinical Pharmacology, National Cancer Center Research Institute, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/srep19772DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4728441PMC
January 2016

Phase 1 study of galunisertib, a TGF-beta receptor I kinase inhibitor, in Japanese patients with advanced solid tumors.

Cancer Chemother Pharmacol 2015 Dec 3;76(6):1143-52. Epub 2015 Nov 3.

Department of Thoracic Oncology, National Cancer Center Hospital, Tsukiji 5-1-1, Chuo-ku, Tokyo, 104-0045, Japan.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s00280-015-2895-4
Publisher Site
http://dx.doi.org/10.1007/s00280-015-2895-4DOI Listing
December 2015

Development of Novel PET Probes for Central 2-Amino-3-(3-hydroxy-5-methyl-4-isoxazolyl)propionic Acid Receptors.

J Med Chem 2015 Nov 2;58(21):8444-62. Epub 2015 Nov 2.

Molecular Imaging Center, National Institute of Radiological Sciences , 4-9-1 Anagawa, Inage-ku, Chiba, Chiba 263-8555, Japan.

View Article

Download full-text PDF

Source
http://pubs.acs.org/doi/10.1021/acs.jmedchem.5b00712
Publisher Site
http://dx.doi.org/10.1021/acs.jmedchem.5b00712DOI Listing
November 2015

Phase II study of amrubicin at a dose of 45 mg/m2 in patients with previously treated small-cell lung cancer.

Jpn J Clin Oncol 2015 Oct 31;45(10):941-6. Epub 2015 Jul 31.

Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jjco/hyv107DOI Listing
October 2015

A phase I study of resminostat in Japanese patients with advanced solid tumors.

Cancer Chemother Pharmacol 2015 Jun 7;75(6):1155-61. Epub 2015 Apr 7.

Department of Thoracic Oncology, National Cancer Center Hospital, 5-1-1, Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-015-2741-8DOI Listing
June 2015

Current Status of Single-Agent Phase I Trials in Japan: Toward Globalization.

J Clin Oncol 2015 Jun 27;33(18):2051-61. Epub 2015 Apr 27.

All authors: National Cancer Center Hospital, Tokyo, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2014.58.4953DOI Listing
June 2015